The Motley Fool Previous Page


Will Agilent's Split Help It Fend Off Danaher and General Electric?

http://www.fool.com/investing/general/2013/11/12/will-agilents-split-help-it-fend-off-danaher-and-g.aspx

Dan Caplinger
November 12, 2013

Agilent Technologies (NYSE: A) will release its quarterly report on Thursday, and shareholders of the measurement and bio-analytics company have been quite pleased by the company's recent move to break itself into two component parts. Yet even if investors are happy about the potential unlocking of shareholder value, the bigger question is whether the move will make Agilent more competitive against Danaher's (NYSE: DHR) diagnostics business and potentially keep General Electric (NYSE: GE) from emphasizing the health-care side of its conglomerate business more heavily than it has lately.

Agilent Technologies bills itself as the world's premier measurement company, making products in the life sciences and chemical analysis areas as well as in electronics and communications. Originally spun off from Hewlett-Packard in 1999, Agilent still owes much of its recent progress to the vision that the two founders of HP instilled in its corporate culture. But as the success of Agilent, Danaher, and other players in the industry attracts potential new entrants like General Electric, competition is only likely to get fiercer. Let's take an early look at what's been happening with Agilent Technologies over the past quarter and what we're likely to see in its report.

Stats on Agilent Technologies

Analyst EPS Estimate

$0.76

Change From Year-Ago Earnings

(11.6%)

Revenue Estimate

$1.71 billion

Change From Year-Ago Revenue

(3.3%)

Earnings Beats in Past 4 Quarters

3

Source: Yahoo! Finance.

Will Agilent Technologies be better off divided than united?
In recent months, analysts have gotten a bit more enthusiastic about Agilent's earnings prospects, boosting fiscal 2013 estimates by about 2% and fiscal 2014 projections by almost 1%. The stock has done well, climbing 11% since early August.

Agilent came into the quarter on a mixed note, as its July quarter earnings fell more than 30% but still eclipsed what investors had expected from the company. The company's life sciences, chemical analysis, and diagnostics and genomics divisions managed to boost sales, but its electronic measurement division suffered declines in revenue. Agilent gave fairly solid guidance for its full fiscal year, guiding to the top end of its earnings range but toward the lower end of previous revenue projections.

But the big news for Agilent came in September, when it combined its life sciences and diagnostics and genomics businesses and announced that it would break into two parts, separating off its electronic measurement division from the rest of the business. Doing so will put the EM business up against Danaher, which makes instruments and mon